Skip to main content
TipRanks
Go Ultimate75% OFF

Medical System Network Co., Ltd. (4350) AI Stock Analysis

0 Followers
JP:4350

Medical System Network Co., Ltd.

(TSE/TYO:4350)

Select Model
Rating:43Neutral
Price Target:JPY 490.00â–¼(-2.20% Downside)
Action:reiterated
Date:11/18/26

The overall score is very low, driven primarily by a severe deterioration in cash flows, which turned deeply negative. This critical financial weakness is compounded by declining profit margins and bearish technical signals, with the stock trading below key moving averages. A moderate valuation and modest dividend yield provide little support against these significant risks.

Positive Factors
Resilient Revenue GrowthSteady revenue growth through 2026 indicates resilient demand for the company’s healthcare IT and services offering. A growing top line provides a recurring base for operating scale, supports continued customer engagement, and creates scope for future earnings recovery.
Negative Factors
Earnings CompressionRepeated net income declines and thin operating profitability weaken the company’s earnings quality despite continued revenue growth. If this compression persists, it can limit internal funding capacity, reduce resilience to cost pressures, and constrain the benefits of future sales expansion.

Medical System Network Co., Ltd. (4350) vs. iShares MSCI Japan ETF (EWJ)

-20%-10%0%10%20%30%40%JP:4350-0.49%EWJ+15.53%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 14.44B
Dividend Yield
2.40%
Average Volume (3M)
99.08K
Price to Earnings (P/E)
21.4
Beta (1Y)
0.29
Revenue Growth
6.89%
EPS Growth
-55.21%
Country
Japan
Employees
4,014
Sector
Healthcare
Sector Strength
51
Industry
Medical - Pharmaceuticals

Medical System Network Co., Ltd. Business Overview & Revenue Model

Company Description

Headquartered in Sapporo, Japan, and established in 1999, Medical System Network Co., Ltd. functions as a comprehensive provider within the healthcare industry. Its core business involves the distribution of pharmaceutical products to a diverse range...

Medical System Network Co., Ltd. Financial Statement Overview

Summary

Financial performance is weak. While revenue growth is positive, profitability is deteriorating with declining margins. Most critically, operating and free cash flow turned sharply negative in the latest year, indicating severe liquidity strain. The deleveraged balance sheet is a positive, but it is overshadowed by the cash flow crisis.

Income Statement

40Negative

Balance Sheet

55Neutral

Cash Flow

20Very Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue134.23B132.19B122.39B115.36B109.55B106.69B
Gross Profit54.03B52.77B49.60B47.93B45.92B44.43B
EBITDA6.28B6.73B6.42B6.90B6.25B7.05B
Net Income870.00M1.07B1.26B1.86B1.61B2.39B
Balance Sheet
Total Assets79.29B80.10B70.63B68.19B66.27B62.98B
Cash, Cash Equivalents and Short-Term Investments7.28B7.74B8.46B8.27B8.14B8.20B
Total Debt30.51B37.67B29.79B29.18B30.52B29.57B
Total Liabilities62.16B62.68B54.28B52.97B51.78B49.69B
Stockholders Equity17.00B17.29B16.26B15.17B14.45B13.27B
Cash Flow
Free Cash Flow0-5.93B1.75B5.62B3.37B1.88B
Operating Cash Flow0-3.44B4.46B7.72B4.97B4.01B
Investing Cash Flow0-4.04B-3.73B-3.65B-2.11B-2.51B
Financing Cash Flow06.79B-544.00M-3.94B-2.92B-3.42B

Medical System Network Co., Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price501.00

Price Trends

50DMA515.07Negative
100DMA497.57Positive
200DMA500.99Positive

Market Momentum

MACD-0.87Positive
RSI40.52Neutral
STOCH5.23Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4350, the sentiment is Negative. The current price of 501.00 is below the 20-day moving average (MA) of 528.55, below the 50-day MA of 515.07, and above the 200-day MA of 500.99, indicating a neutral trend. The MACD of -0.87 indicates Positive momentum. The RSI at 40.52 is Neutral, neither overbought nor oversold. The STOCH value of 5.23 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4350.

Medical System Network Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:4350 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:9989JP:998982OutperformJPY 485.47B15.4411.04%3.18%3.99%-0.48%
JP:3391JP:339181OutperformJPY 1.11T19.857.13%1.90%――
JP:7649JP:764969NeutralJPY 547.39B17.599.94%1.24%8.97%-29.54%
JP:3549JP:354967NeutralJPY 473.20B24.86―1.62%12.54%15.87%
JP:3349JP:334960NeutralJPY 520.98B15.87―1.29%8.99%3.61%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4350JP:435043NeutralJPY 15.33B21.44―2.40%6.89%-55.21%

* Healthcare Sector Average

Performance Comparison

-20%0%20%JP:4350JP:9989JP:7649JP:3391JP:3349JP:3549Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4350 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4350Medical System Network Co., Ltd.501.0011.202.29%
JP:9989Sundrug Co 4152.00-6.76-0.16%
JP:7649Sugi Holdings Co 1408.50-394.14-21.86%
JP:3391TSURUHA Holdings 2469.50-299.95-10.83%
JP:3349COSMOS Pharmaceutical Corporation6371.00-969.33-13.21%
JP:3549KUSURI NO AOKI HOLDINGS CO.,LTD.4949.001081.6827.97%

Medical System Network Co., Ltd. Corporate Events

Medical System Network Reports 4.7% First-Quarter Sales Growth

Nov 17, 2026

Medical System Network Co., Ltd. has businesses in the medical field, including community pharmacy, medical support and medical supply, as well as leasing and facilities, meal catering and home-visit nursing. In the first quarter of the fiscal year e...

Medical System Network Reports Six-Month Sales Growth, Profit Declines

Nov 10, 2026

Medical System Network Co., Ltd. reported consolidated sales of ¥66,887 million for the six months ended September 30, 2026, up 4.7% year over year. EBITDA fell 21.0% to ¥2,365 million, while operating profit declined 44.7% to ¥710 million, ordinary...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 18, 2026